Abstract

In order to improve the effectiveness of spinal anaesthesia, the drug dexmedetomidine, which is a selective alpha2 adrenoceptor agonist, has been employed. The purpose of this research was to determine the ideal dose of dexmedetomidine for intrathecal administration during procedures involving the lower abdomen. Methods: Study was conducted at Lifeline hospital Abu Dhabi between 2021 – 2022. One hundred adult patients with ASA I and ASA II were enrolled in this trial that was randomised, controlled, and blinded on both sides. They were divided up into the five groups as C, D1,D2,D3 and D4. Patients who were allergic to the medications that were going to be utilised in the trial, as well as patients who already had neurological disorders, coagulopathies, heart ailments, obesity, or hypertension, were not allowed to participate in the research. Result: The control group experienced a mean analgesia duration of 201 minutes, while the D1 group experienced 259.1 minutes, the D2 group experienced 310.1 minutes, the D3 group experienced 540 minutes, and the D4 group experienced 702.4 minutes. The D3 and D4 groups had hypotension that needed to be treated, but the Dexemeditomidine groups had much reduced mean maximum VRS ratings and analgesic requirements.

Description